Published in Value Health on October 26, 2009
An economic assessment model for in-center, conventional home, and more frequent home hemodialysis. Kidney Int (2011) 1.08
Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. J Neurol (2012) 0.95
The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: Methodological recommendations. Saudi Pharm J (2011) 0.77
Beyond AWP . . . way beyond. Value Health (2009) 0.76
Methods to construct a step-by-step beginner's guide to decision analytic cost-effectiveness modeling. Clinicoecon Outcomes Res (2016) 0.75
What's in a perspective? Value Health (2009) 0.75
Cross-national comparison of medical costs shared by payers and patients: a study of postmenopausal women with early-stage breast cancer based on assumption case scenarios and reimbursement fees. Breast Care (Basel) (2013) 0.75
Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss. Pharmacoeconomics (2017) 0.75
Early appraisal of China's huge and complex health-care reforms. Lancet (2012) 7.71
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health (2013) 4.22
Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm (2003) 3.34
A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet (2002) 3.26
Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care (2003) 2.33
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics (2013) 2.21
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ (2013) 2.21
Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants. Breastfeed Med (2011) 2.12
[CONSORT 2010 Declaration: updated guideline for reporting parallel group randomised trials]. Med Clin (Barc) (2011) 2.10
Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. Health Policy (2009) 1.94
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health (2013) 1.89
Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol (2010) 1.84
What do international pharmacoeconomic guidelines say about economic data transferability? Value Health (2010) 1.74
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care (2013) 1.66
Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis (2004) 1.65
Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study. Value Health (2011) 1.53
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Clin Ther (2013) 1.53
Amniocentesis and informed consent. Br Med J (Clin Res Ed) (1988) 1.52
Estimation and comparison of EQ-5D health states' utility weights for pneumococcal and human papillomavirus diseases in Argentina, Chile, and the United Kingdom. Value Health (2011) 1.51
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. J Med Econ (2013) 1.49
Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther (2004) 1.46
Where's the value in health care? Value Health (2006) 1.45
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Med (2013) 1.44
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health (2009) 1.43
A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Value Health (2003) 1.43
Determination of the longitudinal validity and minimally important difference of the 8-item Parkinson's Disease Questionnaire (PDQ-8). Mov Disord (2009) 1.40
[Decision analysis: diagnostic approach in HIV infection associated chronic diarrhea]. Acta Gastroenterol Latinoam (2005) 1.37
Using evidence in the development of local health policies. Some evidence from the United Kingdom. Int J Technol Assess Health Care (2002) 1.35
Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health (2005) 1.32
Drug-related problems in hospitalized patients on polypharmacy: the influence of age and gender. Ther Clin Risk Manag (2005) 1.29
Can economic evaluations be made more transferable? Eur J Health Econ (2005) 1.27
Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm (2006) 1.26
Best practice in undertaking and reporting health technology assessments. Working group 4 report. Int J Technol Assess Health Care (2002) 1.25
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
Economic evaluation of health interventions. BMJ (2008) 1.19
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab (2004) 1.15
EBM, HTA, and CER: clearing the confusion. Milbank Q (2010) 1.15
Improving medical device regulation: the United States and Europe in perspective. Milbank Q (2014) 1.13
Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health (2003) 1.09
The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health (2007) 1.08
Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health (2010) 1.08
Evaluating the cost-effectiveness of statins. J Manag Care Pharm (2004) 1.08
Retaining, and enhancing, the QALY. Value Health (2009) 1.08
Health economic evaluation: important principles and methodology. Laryngoscope (2013) 1.05
Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health (2005) 1.05
Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Eff Resour Alloc (2009) 1.02
The effectiveness and cost-effectiveness of respite for caregivers of frail older people. J Am Geriatr Soc (2007) 1.01
A research agenda for economic evaluation of substance abuse services. J Subst Abuse Treat (2005) 1.00
Applying health economics for policy decision making: do devices differ from drugs? Europace (2011) 0.99
Guidelines for completing the EURONHEED transferability information checklists. Eur J Health Econ (2008) 0.99
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value Health (2009) 0.98
Spanish cross-cultural adaptation and validation of the National Institutes of Health Stroke Scale. Mayo Clin Proc (2006) 0.98
Where do I send thee? Does physician-ownership affect referral patterns to ambulatory surgery centers? Health Aff (Millwood) (2008) 0.98
Health-care systems and pharmacoeconomic research in Asia-Pacific region. Value Health (2008) 0.98
A new algorithm to identify the causality of adverse drug reactions. Drug Saf (2005) 0.97
Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III. Value Health (2009) 0.96
Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V. Value Health (2009) 0.96
Understanding the underlying drivers of inpatient cost growth: a literature review. Am J Manag Care (2003) 0.96
Validity and reliability of the PDQ-39 and the PDQ-8 in English-speaking Parkinson's disease patients in Singapore. Parkinsonism Relat Disord (2004) 0.95
Moving the QALY forward: rationale for change. Value Health (2009) 0.95
Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord (2010) 0.94
Universal coverage and health financing from China's perspective. Bull World Health Organ (2008) 0.93
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Eur J Health Econ (2013) 0.93
Economics methods in Cochrane systematic reviews of health promotion and public health related interventions. BMC Med Res Methodol (2006) 0.93
Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacoeconomics (2009) 0.92
Health technology assessment for resource allocation decisions: are key principles relevant for Latin America? Int J Technol Assess Health Care (2010) 0.92
Medical technology as a key driver of rising health expenditure: disentangling the relationship. Clinicoecon Outcomes Res (2013) 0.92
Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine (2009) 0.91
Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. Am J Manag Care (2003) 0.91
Valuing health for clinical and economic decisions: directions relevant for rheumatologists. J Rheumatol (2011) 0.91
Another special relationship? Interactions between health technology policies and health care systems in the United States and the United Kingdom. J Health Polit Policy Law (2011) 0.91
Experiences and barriers to implementation of clinical practice guideline for depression in Korea. BMC Psychiatry (2013) 0.90
National drug policies to local formulary decisions in Thailand, China, and Australia: drug listing changes and opportunities. Value Health (2012) 0.89
Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries. Vaccine (2011) 0.89
The desirability and feasibility of economic studies of drugs post-launch. Eur J Health Econ (2006) 0.89
Issues for countries considering introducing the "fourth hurdle": the case of Hungary. Int J Technol Assess Health Care (2004) 0.89
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Cost Eff Resour Alloc (2013) 0.88
Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. BMC Pediatr (2013) 0.88
Assessing the appropriateness of combining economic data from multinational clinical trials. Stat Med (2003) 0.88
Investigating differential item functioning by chronic diseases in the SF-36 health survey: a latent trait analysis using MIMIC models. Med Care (2007) 0.88
[Estimate of the cardiovascular disease burden attributable to modifiable risk factors in Argentina]. Rev Panam Salud Publica (2010) 0.88
Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? Eur J Health Econ (2012) 0.88
Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. J Diabetes Complications (2010) 0.88
The lag between effectiveness and cost-effectiveness evidence of new drugs. Implications for decision-making in health care. Eur J Health Econ (2003) 0.87
Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. Am J Geriatr Psychiatry (2011) 0.87
The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol (2013) 0.87